An in vivo imaging system was used for bioluminescence imaging (BLI) to visualize ASID mice with bone metastases of LNCaP-luc prostate cancer before the administration of 177Lu-PSMA-617 (Figure 4A). This evidence concerns the gene FOLH1 and prostate cancer.